Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Is bevacizumab effective and safe in combination with chemotherapy in patients with colorectal cancer?

Nature Clinical Practice Oncology volume 4, pages 214–215 (2007)Cite this article

boxed-textGiantonio BJ et al. (2006) A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200. Ann Oncol 17: 1399–1403

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Hurwitz H et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335–2342

    Article  CAS  Google Scholar 

  2. Giantonio B et al. (2005) High-dose bevacizumab in combination with FOLFOX4 improves survival in patients with previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200 [abstract]. J Clin Oncol 23 (Suppl): aS2

    Article  Google Scholar 

  3. de Gramont A et al. (2005) Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer. Oncology 69 (Suppl 3): 46–56

    Article  CAS  Google Scholar 

  4. Kabbinavar F et al. (2003) Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21: 60–65

    Article  CAS  Google Scholar 

  5. Jain RK (2003) Molecular regulation of vessel maturation. Nat Med 9: 685–693

    Article  CAS  Google Scholar 

  6. Cassidy J et al. (2006) First efficacy and safety results from XELOX-1/NO16966, a randomised 2x2 factorial phase III trial of XELOX vs FOLFOX4 + bevacizumab or placebo in first-line metastatic colorectal cancer (MCRC) [abstract]. Ann Oncol 17 (Suppl 9): LBA 3

    Google Scholar 

Download references

Acknowledgements

The synopsis was written by Petra Roberts, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. HE Uronis is a Fellow and HI Hurwitz is an Associate Professor in the Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, NC, USA.,

    Hope E Uronis & Herbert I Hurwitz

Authors
  1. Hope E Uronis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Herbert I Hurwitz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Herbert I Hurwitz.

Ethics declarations

Competing interests

HI Hurwitz has declared associations with the following companies: Genentech, Roche. See the article online for full details of the relationship. HE Uronis declared she has no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Uronis, H., Hurwitz, H. Is bevacizumab effective and safe in combination with chemotherapy in patients with colorectal cancer?. Nat Rev Clin Oncol 4, 214–215 (2007). https://doi.org/10.1038/ncponc0748

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc0748

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing